title: Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
abstract: BACKGROUND
  The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test.
  
  
  METHODS
  The maximum tolerated dose (MTD) and recommended dose (RD) of intravenous (i.v.) Bortezomib (B) (days 1, 4, 8, 11) and i.v. Paclitaxel (PTX) (days 1, 8) every 3 weeks was evaluated in patients with advanced solid tumours. The RD was tested in patients with breast, ovarian and prostate cancer. At the RD, microarray analysis of transcriptional profiles was carried out before and after the first dosing in peripheral blood mononuclear cells (PBMC).
  
  
  RESULTS
  Thirty-one patients were enrolled and 22 were treated at the RD that corresponded to B 1.3mg/m(2) and PTX 100mg/m(2). The main toxicity was cumulative peripheral neuropathy (76% of patients; grade 3-4 in 9%) that required treatment discontinuation in six patients, followed by diarrhoea (55%) and fatigue (41%). Nine partial responses (30%) were observed (three breast cancer, four ovary, two prostate patients). Significant (p<0.05) and consistent changes (>70% of patients) in transcriptome were observed.
  
  
  CONCLUSIONS
  The incidence of peripheral neuropathy and the anti-tumour activity comparable to that of single-agent PTX do not support further development of this regimen.
authors.affiliation: Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Cresta
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: C V
authors.initials: CV
authors.lastname: Catapano
authors.forename: E
authors.initials: E
authors.lastname: Gallerani
authors.forename: D
authors.initials: D
authors.lastname: Passalacqua
authors.forename: A
authors.initials: A
authors.lastname: Rinaldi
authors.forename: F
authors.initials: F
authors.lastname: Bertoni
authors.forename: L
authors.initials: L
authors.lastname: Viganò
authors.forename: M
authors.initials: M
authors.lastname: Maur
authors.forename: G
authors.initials: G
authors.lastname: Capri
authors.forename: E
authors.initials: E
authors.lastname: Maccioni
authors.forename: D
authors.initials: D
authors.lastname: Tosi
authors.forename: L
authors.initials: L
authors.lastname: Gianni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D017239:Paclitaxel